Teva Pharmaceutical Reports Q2 2026 Financial Results

What Happened
Teva Pharmaceutical Industries Ltd. announced its financial results for the quarter ended June 30, 2026 in a press release issued July 29, 2026. The company furnished the press release as Exhibit 99.1 to the Form 8-K filed the same day; the filing was signed by Eli Kalif, Executive Vice President and Chief Financial Officer.

Key Details

• The press release reporting Q2 2026 results was issued and furnished as Exhibit 99.1 to the Form 8-K (filed July 29, 2026).
• The reporting period covered is the quarter ended June 30, 2026.
• The Form 8-K includes an Inline XBRL cover page (interactive data file embedded).
• The report was signed by Eli Kalif, EVP and CFO, on behalf of the company.

Why It Matters
This 8-K signals that Teva’s quarterly earnings and related financial metrics (revenue, earnings, cash flow and any guidance) are available to investors in the company’s press release and accompanying disclosures. Retail investors should review the furnished press release and any subsequent SEC filings (e.g., Form 10-Q) for the specific numbers and management commentary to assess Teva’s recent performance and any implications for valuation or investment decisions. Keywords: earnings, quarterly results, revenue, financial results, CFO.